StockData
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. (SANA) stock

SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.74−0.11 (-5.95%)

Close on Nov 19, 2026Market cap $520.89MP/E –Yield –

Sana Biotechnology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Sana Biotechnology's operating income for the twelve months ending Jun 30, 2026 was -$218.75M. For fiscal 2025 it was -$250.32M. The highest annual figure on record is -$141.15M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$250.32M–
FY2024Dec 31, 2024-$272.72M–
FY2023Dec 31, 2023-$293.14M–
FY2022Dec 31, 2022-$272.56M–
FY2021Dec 31, 2021-$356.91M–
FY2020Dec 31, 2020-$286.15M–
FY2019Dec 31, 2019-$141.15M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$65.42M–
Q1 FY2026Mar 31, 2026-$48.61M–
Q4 FY2025Dec 31, 2025-$61.20M–
Q3 FY2025Sep 30, 2025-$43.52M–
Q2 FY2025Jun 30, 2025-$94.98M–
Q1 FY2025Mar 31, 2025-$50.63M–
Q4 FY2024Dec 31, 2024-$50.87M–
Q3 FY2024Sep 30, 2024-$61.76M–
Q2 FY2024Jun 30, 2024-$49.37M–
Q1 FY2024Mar 31, 2024-$110.72M–
Q4 FY2023Dec 31, 2023-$90.62M–
Q3 FY2023Sep 30, 2023-$2.18M–
Q2 FY2023Jun 30, 2023-$116.29M–
Q1 FY2023Mar 31, 2023-$84.05M–
Q4 FY2022Dec 31, 2022-$81.79M–
Q3 FY2022Sep 30, 2022-$86.19M–
Q2 FY2022Jun 30, 2022-$72.90M-493.0%
Q1 FY2022Mar 31, 2022-$31.69M–
Q4 FY2021Dec 31, 2021-$111.28M–
Q3 FY2021Sep 30, 2021-$83.43M–
Q2 FY2021Jun 30, 2021$18.55M–
Q1 FY2021Mar 31, 2021-$180.75M–
Q4 FY2020Dec 31, 2020-$113.32M–
Q3 FY2020Sep 30, 2020-$51.64M–
Q2 FY2020Jun 30, 2020-$87.91M–
Q1 FY2020Mar 31, 2020-$33.28M–

More Sana Biotechnology figures

See a number that looks wrong?